Georgescu C
Med Interne. 1985 Apr-Jun;23(2):135-40.
Specific immunotherapy with transfer factor (TF) was used in a chronic experiment in a group of 50 female patients with rheumatoid arthritis (RA) stage I-III. The patients were followed up for 24 months, clinical and biologic examinations being repeated every 3 months. In this period the patients received beside the basic nonsteroid antiinflammatory therapy, one unit TF every week over a period of 6 months then one until TF every month (10 patients) to the end of experiment. Of the 50 patients 15 (30%) did not respond to the therapy and the experiments had to be interrupted after 6 months. Excellent, very good and good results were obtained in 35 patients (70%). In 12 patients the response was good but the dose of TF had to be increased to two units/week in the first 6 months. In 13 patients the results obtained were very good and therapy with nonsteroid products + TF was continued even after the first 6 months. In 10 patients with RA stage I the results obtained were excellent and after 6 months the nonsteroid therapy could be interrupted and the therapy was continued only with one unit TF every month. The study confirmed the fact that specific immunotherapy with TF represents an important adjuvant in the treatment of rheumatoid arthritis (RA).
对一组50名处于I - III期类风湿性关节炎（RA）的女性患者进行了一项慢性实验，采用转移因子（TF）进行特异性免疫治疗。对患者进行了24个月的随访，每3个月重复进行临床和生物学检查。在此期间，患者除了接受基本的非甾体抗炎治疗外，在6个月内每周接受1单位TF治疗，然后在实验结束前每月接受1单位TF治疗（10名患者）。50名患者中有15名（30%）对治疗无反应，6个月后实验不得不中断。35名患者（70%）获得了优秀、非常好和好的结果。12名患者反应良好，但在前6个月TF剂量不得不增加到每周2单位。13名患者获得了非常好的结果，即使在前6个月后，非甾体产品 + TF治疗仍继续进行。10名处于I期RA的患者获得了优异的结果，6个月后非甾体治疗可以中断，仅每月用1单位TF继续治疗。该研究证实了TF特异性免疫治疗是类风湿性关节炎（RA）治疗中一种重要辅助治疗方法这一事实。
